Search Results - "Nole, F"

Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy by Aapro, M., Fabi, A., Nolè, F., Medici, M., Steger, G., Bachmann, C., Roncoroni, S., Roila, F.

“…Background: To reduce side-effects of corticosteroid-containing antiemetic regimens, tailoring antiemetic schedules to specific requirements of different…”
Get full text

A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck by Bossi, P., Miceli, R., Locati, L.D., Ferrari, D., Vecchio, S., Moretti, G., Denaro, N., Caponigro, F., Airoldi, M., Moro, C., Vaccher, E., Sponghini, A., Caldara, A., Rinaldi, G., Ferrau, F., Nolè, F., Lo Vullo, S., Tettamanzi, F., Hollander, L., Licitra, L.

“…B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b, noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin…”
Get full text

A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin by Bossi, P., Cortinovis, D., Fatigoni, S., Cossu Rocca, M., Fabi, A., Seminara, P., Ripamonti, C., Alfieri, S., Granata, R., Bergamini, C., Agustoni, F., Bidoli, P., Nolè, F., Pessi, M.A., Macchi, F., Michellini, L., Montanaro, F., Roila, F.

“…The activity of ginger in the management of chemotherapy-induced nausea and vomiting (CINV) has been suggested, but design inadequacies, heterogeneity of the…”
Get full text

Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects by Colleoni, M., Orlando, L., Sanna, G., Rocca, A., Maisonneuve, P., Peruzzotti, G., Ghisini, R., Sandri, M.T., Zorzino, L., Nolè, F., Viale, G., Goldhirsch, A.

“…Background: We previously demonstrated efficacy and impact on serum vascular endothelial growth factor (VEGF) for metronomic cyclophosphamide (C) and…”
Get full text

Cancer–testis antigen expression in triple-negative breast cancer by Curigliano, G., Viale, G., Ghioni, M., Jungbluth, A.A., Bagnardi, V., Spagnoli, G.C., Neville, A.M., Nolè, F., Rotmensz, N., Goldhirsch, A.

“…Background: Cancer–testis (CT) antigens, frequently expressed in human germline cells but not in somatic tissues, may become aberrantly reexpressed in…”
Get full text

Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer by Munzone, Elisabetta, Botteri, E., Sciandivasci, A., Curigliano, G., Nolè, F., Mastropasqua, M., Rotmensz, N., Colleoni, M., Esposito, A., Adamoli, L., Luini, A., Goldhirsch, A., Viale, G.

“…The aim of this analysis was to investigate the usefulness of Ki-67 labeling index (LI) for the identification of different prognostic subgroups in primary…”
Get full text

A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma by Rocca, A, Minucci, S, Tosti, G, Croci, D, Contegno, F, Ballarini, M, Nolè, F, Munzone, E, Salmaggi, A, Goldhirsch, A, Pelicci, P G, Testori, A

“…We explored in a phase I/II clinical trial the combination of valproic acid (VPA), a clinically available histone deacetylase inhibitor, with standard…”
Get full text

Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how? by Marvaso, G., Corrao, G., Oneta, O., Pepa, M., Zaffaroni, M., Corso, F., Gandini, S., Cecconi, A., Zerini, D., Mazzola, G. C., Augugliaro, M., Cossu Rocca, M., Verri, E., Cattani, F., La Fauci, F., Bergamaschi, L., Luzzago, S., Mistretta, A. F., Musi, G., Nolè, F., De Cobelli, O., Orecchia, R., Jereczek-Fossa, B. A.

“…Background and purpose Renal cell carcinoma (RCC) has traditionally been considered radioresistant with a limited role for conventional fractionation as a…”
Get full text

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort by Fornarini, G., Rebuzzi, S.E., Banna, G.L., Calabrò, F., Scandurra, G., De Giorgi, U., Masini, C., Baldessari, C., Naglieri, E., Caserta, C., Manacorda, S., Maruzzo, M., Milella, M., Buttigliero, C., Tambaro, R., Ermacora, P., Morelli, F., Nolè, F., Astolfi, C., Sternberg, C.N.

“…Reliable and affordable prognostic and predictive biomarkers for urothelial carcinoma treated with immunotherapy may allow patients' outcome stratification and…”
Get full text

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99 by Pagani, O., Klingbiel, D., Ruhstaller, T., Nolè, F., Eppenberger, S., Oehlschlegel, C., Bernhard, J., Brauchli, P., Hess, D., Mamot, C., Munzone, E., Pestalozzi, B., Rabaglio, M., Aebi, S., Ribi, K., Rochlitz, C., Rothgiesser, K., Thürlimann, B., von Moos, R., Zaman, K., Goldhirsch, A.

“…HER2-targeted therapy plus chemotherapy is standard treatment in advanced HER2+ breast cancer. Trastuzumab alone followed by addition of chemotherapy at…”
Get full text

Very young women (<35 years) with operable breast cancer: features of disease at presentation by COLLEONI, M, ROTMENSZ, N, CATALANO, G, GALIMBERTI, V, NOLE, F, MARTINELLI, G, GOLDHIRSCH, A, ROBERTSON, C, ORLANDO, L, VIALE, G, RENNE, G, LUINI, A, VERONESI, P, INTRA, M, ORECCHIA, R

“…Breast cancer rarely occurs in young women. Our knowledge about disease presentation, prognosis and treatment effects are largely dependent upon older series…”
Get full text

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels by COLLEONI, M, ROCCA, A, DE BRAUD, F, VIALE, G, GOLDHIRSCH, A, SANDRI, M. T, ZORZINO, L, MASCI, G, NOLE, F, PERUZZOTTI, G, ROBERTSON, C, ORLANDO, L, CINIERI, S

“…Anticancer chemotherapy is thought to be effective by means of direct cytotoxicity on tumor cells. Alternative mechanisms of efficacy have been ascribed to…”
Get full text

Sunitinib 2 weeks on, 1 off: strengths and weaknesses by Iacovelli, R., Verri, E., Cossu Rocca, M., Aurilio, G., Cullurà, D., Nolé, F.

Get full text

Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors by Sanna, G., Lorizzo, K., Rotmensz, N., Bagnardi, V., Cinieri, S., Colleoni, M., Nolè, F., Goldhirsch, A.

“…Background: Better therapeutic approaches for patients with Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL) resulted in high cure rates, at cost of…”
Get full text

Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer by Sanna, G, Preda, L, Bruschini, R, Cossu Rocca, M, Ferretti, S, Adamoli, L, Verri, E, Franceschelli, L, Goldhirsch, A, Nolè, F

“…Background: In recent years, several cases of mandibular necrosis associated with long-term use of bisphosphonates have been reported. The estimated incidence…”
Get full text

Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology by Alterio, D., Cossu Rocca, M., Russell-Edu, W., Dicuonzo, S., Fanetti, G., Marvaso, G., Preda, L., Zorzi, S., Verri, E., Nole’, F., Jereczek-Fossa, B. A.

“…Many concerns are related to the idea that the acute toxicity of induction chemotherapy (IC) performed with TPF (docetaxel, cisplatin, 5-fluorouracil) could…”
Get full text

Jaw avascular bone necrosis associated with long-term use of biphosphonates by Sanna, G., Zampino, M. G., Pelosi, G., Nolè, F., Goldhirsch, A.

Get full text

Activity of fulvestrant in HER2-overexpressing advanced breast cancer by Robertson, J.F.R., Steger, G.G., Neven, P., Barni, S., Gieseking, F., Nolè, F., Pritchard, K.I., O'Malley, F.P., Simon, S.D., Kaufman, B., Petruzelka, L.

“…Human epidermal growth factor receptor 2 (HER2) overexpression increases the aggressiveness of breast cancer cells resulting in poorer prognosis. Patients with…”
Get full text

Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer by Nolè, F., Catania, C., Sanna, G., Imadalou, K., Munzone, E., Adamoli, L., Longerey, B., Blanchot, G., Goldhirsch, A.

“…Purpose: A phase I study was performed to determine the maximal tolerated dose, recommended doses (RDs), safety and efficacy of oral vinorelbine when combined…”
Get full text

Totally implantable central venous access ports for long-term chemotherapy : A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days by BIFFI, R, DE BRAUD, F, ORSI, F, POZZI, S, MAURI, S, GOLDHIRSCH, A, NOLE, F, ANDREONI, B

“…A few data are available from analyses of the complications and costs of central venous access ports for chemotherapy. This prospective study deals with the…”
Get full text